SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
CytomX provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets. CytomX and Amgen are developing CX-904, a T-cell-engaging bispecific Probody candidate against the ...
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the ...
Investigators have discovered the mechanisms underlying a T-cell receptor's immunosuppressive function, according to a study published Nature Immunology, findings that may provide insight into the ...
This is an illustration of how the engineered protein facilitates destruction of latently HIV-infected immune cells. 1) Protein and cells, from left to right: engineered protein with yellow-and-black ...
A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback